Sentence examples for eligible for cart from inspiring English sources

Although only 48% of patients eligible for cART were receiving cART at assessment for deterioration, it is likely that some patients subsequently initiated cART.

Among HIV-positive women whose CD4 count results were available, 47% were eligible for cART.

[ 12] Women eligible for cART are those with absolute CD4 count ≤ 350 cells/mm3 (regardless of clinical stage) and women in WHO clinical stage 4 (irrespective of absolute CD4 count).

The immunologic threshold for cART initiation was increased from a CD4+ T cell (CD4) count of 200 cells/μL to 350 cells/μL, effectively increasing the number of patients eligible for cART.

Individuals were eligible for cART if they: (a) had a WHO stage 4 disease, (b) had proven tuberculosis and a CD4 cell count between 200 and 350 cells/μl, (c) had a CD4 cell count below <200 cells/μl or (d) were pregnant irrespective of CD4 cell count.

Of those women, 2,528 (17.1%) had their blood sample collected for CD4 count assessment; of those, 1,680 (66.5%) had CD4 count results available at PHCs; of those, 796 (47.4%) had CD4 count ≤ 350 cells/mm3 and thus were eligible for cART; and of those, 581 (73.0%) were initiated on cART.

Of 14,815 HIV-positive pregnant women registered in the 60 PHCs, 2,528 (17.1%) had their CD4 cells counted; of those, 1,680 (66.5%) had CD4 count results available at PHCs; of those, 796 (47.4%) had CD4 count ≤ 350 cells/mm3 and thus were eligible for combination antiretroviral treatment (cART); and of those, 581 (73.0%) were initiated on cART.

[ 7, 13, 14] Across the 12 months of observation, there was an increase in the proportion of HIV-positive pregnant women assessed for CD4 count, the proportion of CD4 count results available at PHCs, and the proportion of HIV-positive women eligible for treatment who initiated cART.

Individuals were eligible if ≥18 years and met criteria for cART initiation in the government-sponsored HIV treatment programme, i.e. a CD4+ count ≤350 cells/mm.

Historically, women living with HIV not yet eligible for life-long combination antiretroviral therapy (cART) used short-course cART or zidovudine monotherapy in pregnancy to prevent mother-to-child transmission, before initiating life-long treatment when their CD4+ cell count reached a specified level.

The majority (73.0%) of women identified eligible for ART were initiated on cART; however, a minority (11.3%) of HIV-positive pregnant women were assessed for CD4 count and had their test results available.